FDA Approves Treg Cell Therapy - Summary - MDSpire
Advertisement
FDA Approves Treg Cell Therapy
A randomized clinical trial found higher chronic GVHD-free survival and lower rates of serious chronic GVHD compared with standard transplantation in adults with blood cancers.
To improve chronic graft-versus-host disease-free survival in adult patients with blood cancers undergoing allogeneic hematopoietic stem cell transplantation.
Approach:
Therapy Description: Tregzi is a donor-derived cellular immunotherapy composed of purified hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells collected from an 8/8 human leukocyte antigen-matched donor.
Clinical Trial: The approval was based on the PRECISION-T trial, which enrolled 187 adult patients with blood cancers, comparing Tregzi to standard stem cell transplant.
Key Findings:
One-year chronic GVHD-free survival was 78% with Tregzi compared to 38% with a standard transplant.
Serious chronic GVHD occurred within 1 year in 13% of patients treated with Tregzi versus 44% in the standard transplant group.
The most common side effects were infections; no severe infusion reactions or graft failures were reported.
Interpretation:
Regulatory T cells help regulate immune responses and maintain immune tolerance, aiming to reduce chronic GVHD risk during immune system reconstitution.
Limitations:
The study's primary endpoint was chronic GVHD-free survival measured over 2 years.
The trial involved a specific patient population with blood cancers.
Conclusion:
Tregzi represents a significant advancement in the treatment of chronic graft-versus-host disease in patients undergoing stem cell transplantation.
A structured framework of diagnostic classifications, reporting frameworks, staging systems, coding resources, and molecular pathology tools used in practice.
A Korean cohort study found fewer kidney cancer cases among patients with type 2 diabetes who initiated sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors.
